View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 14, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Collegium to Report Fourth Quarter and Full-Year 2025 Financial Result...

Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 ...

 PRESS RELEASE

OPKO Health to Report Fourth Quarter 2025 Financial Results on Februar...

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-r...

 PRESS RELEASE

LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 2...

LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026 BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online . All registrants will receive dial-in information and a PIN allowing them to access the li...

 PRESS RELEASE

Angi Inc. Earnings Release and Letter to Shareholders Available on Com...

Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website DENVER, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its fourth-quarter financial results and a letter to shareholders from CEO Jeffrey Kip on the investor relations section of its website at . As announced previously, Angi Inc. will host a conference call to discuss the company’s fourth-quarter results and answer questions. The call will be held on Wednesday, February 11, 2026, at 8:30 a.m. ET. Jeffrey Kip, CEO, and Andrew Russakoff, CFO, will participate. The live audiocast and rep...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 6, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Clas...

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...

 PRESS RELEASE

Inuvo Announces Receipt of $6.2 Million Class Action Settlement

Inuvo Announces Receipt of $6.2 Million Class Action Settlement LITTLE ROCK, Ark., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence-driven data and advertising technology solutions, today announced that it has received $6.2 million as a claimant of a class action lawsuit settlement first referenced in its Q3 2025 investor call and recent shareholder update. “This represents an important financial development for Inuvo,” said Rob Buchner, Inuvo Chairman & CEO. “We are pleased to conclude this matter and receive the settleme...

 PRESS RELEASE

Inuvo Appoints Rob Buchner as Chairman and Chief Executive Officer

Inuvo Appoints Rob Buchner as Chairman and Chief Executive Officer LITTLE ROCK, Ark., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence-driven data and advertising technology solutions, today announced the appointment of Rob Buchner as Chairman of the Board and Chief Executive Officer, effective February 1, 2026. Throughout 2025, Buchner worked closely within Inuvo in an advisory, board, and executive capacity. This experience has provided a comprehensive understanding of the company’s existing markets, strategy, technolo...

 PRESS RELEASE

Inuvo Reports Unaudited Preliminary Fourth Quarter 2025 Revenue Result...

Inuvo Reports Unaudited Preliminary Fourth Quarter 2025 Revenue Results LITTLE ROCK, Ark., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence-driven data and advertising technology solutions, today reported preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. The Company expects fourth-quarter 2025 net revenue to be approximately $14 million, representing an approximate 47% decrease compared to the same quarter of the prior year. The shortfall was driven primarily by an intentional pullback i...

 PRESS RELEASE

Angi Inc. to Announce Q4 2025 Earnings on February 10th and Host Earni...

Angi Inc. to Announce Q4 2025 Earnings on February 10th and Host Earnings Conference Call on February 11th DENVER, Jan. 20, 2026 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, February 10, 2026, Angi Inc. (NASDAQ: ANGI) will post its fourth quarter results and publish CEO Jeff Kip's letter to shareholders, which may include certain forward-looking information, at ir.angi.com/quarterly-earnings. On Wednesday, February 11, 2026, at 8:30 a.m. ET, Angi Inc. will host a conference call to answer questions regarding the company’s fourth quarter results. The live audiocast an...

 PRESS RELEASE

Millennials Are Driving the Future of Home Spending, According to Angi...

Millennials Are Driving the Future of Home Spending, According to Angi’s State of Home Spending Report New data finds Millennials spend more per household on home projects overall than any other generation, reshaping how Americans maintain, upgrade, and live in their homes. DENVER, Jan. 20, 2026 (GLOBE NEWSWIRE) -- reveals that Millennials have become the primary drivers of today’s home projects economy, generating the highest total home spending per household of any generation. While Millennials are not yet the largest group of homeowners, they outspend all other generations on a per-...

 PRESS RELEASE

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annua...

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (A...

 PRESS RELEASE

Collegium Provides 2026 Financial Guidance and Business Update

Collegium Provides 2026 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update. “2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum ...

 PRESS RELEASE

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare C...

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco.  Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors sectio...

 PRESS RELEASE

Collegium Announces the Closing of $980 Million Syndicated Credit Faci...

Collegium Announces the Closing of $980 Million Syndicated Credit Facility Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million credit facility will mature in 2030 and consists of a $580 million initial Term Loan, $300 million Delayed Draw Term Loan, and $100 million revolving credit facility (collectively the “Credit Facility”). The initial Term Loan was used...

 PRESS RELEASE

Inuvo Launches Ranger: AI Tool for Ad Quality and Compliance

Inuvo Launches Ranger: AI Tool for Ad Quality and Compliance LITTLE ROCK, Ark., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence AdTech solutions, today announced the launch of Ranger, an advanced quality assurance and compliance feature within its Campsight system. Campsight is Inuvo’s integrated environment for managing content, campaigns, and regulatory oversight. Ranger is designed to verify that every ad creative is accurate, relevant, and consistent with the page a user sees after clicking the ad. This ensures higher...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch